Determinants of serious liver disease among patients receiving low‐dose methotrexate for rheumatoid arthritis
Open Access
- 1 March 1993
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 36 (3) , 329-335
- https://doi.org/10.1002/art.1780360307
Abstract
Objective. To assess the risk of serious liver disease in patients with rheumatoid arthritis (RA) taking methotrexate (MTX). Methods. We surveyed members of the American College of Rheumatology to determine previous use of MTX in the treatment of rheumatoid arthritis and to identify cases of cirrhosis and liver failure. Cases were confirmed by review of pathology specimens, findings from diagnostic testing, and clinical presentations. A case—control study was then conducted to ascertain prognostic factors. Case and control medical records were reviewed for information on MTX therapy as well as other possible determinants of serious liver disease. Results. Twenty‐four cases of cirrhosis and liver failure were identified, giving a 5‐year cumulative incidence of ˜ 1/1,000 treated patients. Six of the 24 patients had died: 4 died of the initial liver disease, 1 of hepatic complications of another illness, and 1 of unrelated causes. Two patients continue to have active liver disease. Late age at first use of MTX and duration of therapy with MTX were independent predictors of serious liver disease. Conclusion. Serious liver disease is an uncommon, age‐ and dose‐related complication of low‐dose MTX therapy for RA.Keywords
This publication has 12 references indexed in Scilit:
- Long‐Term Prospective Study of Methotrexate in the Treatment of Rheumatoid ArthritisArthritis & Rheumatism, 1992
- Low‐dose methotrexate therapy and hepatotoxicity The view of the hepatologistThe Medical Journal of Australia, 1991
- Electron microscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis. Correlation with light microscopic findingsArthritis & Rheumatism, 1989
- Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long‐term treatmentArthritis & Rheumatism, 1989
- Liver histology in rheumatoid arthritis patients receiving long‐term methotrexate therapy. A Prospective Study with Baseline and Sequential Biopsy SamplesArthritis & Rheumatism, 1989
- Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritisThe American Journal of Medicine, 1988
- Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritisArthritis & Rheumatism, 1988
- Clinical associations between arthritis and liver disease.Annals of the Rheumatic Diseases, 1982
- Methotrexate guidelines—revisedJournal of the American Academy of Dermatology, 1982
- Methotrexate Hepatotoxicity in PsoriasisArchives of Dermatology, 1980